Pharmaceutical Executive, Nov 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Nov 1, 2010
Features
The Fruits of Comparative Effectiveness
By Edward Tuttle , Anita Chawla , Dave Nellesen , Justin Works
New CER tools grant payers the evidence they need to control drug costs
Science and Politics at the FDA
By Walter Armstrong
Harvard professor Daniel Carpenter offers a piercing analysis of the FDA and sheds light on its biggest challenges
The Rx Club
By Jennifer Ringler
The Rx Club Awards have evolved over the years, but the essential 'wow' factor has remained a constant
Columns
Japan: The Real Emerging Market?
By William Looney
With all the money and momentum focused on medicines in emerging markets, it may be time to take a closer look at business opportunities in this more familiar neighbor to the East
Specialty Care Medicines: Managing the Impact of US Health Reform
By John Swen
There's been much talk of how US health reform will impact physicians, patients, and insurance companies. But how will it affect the often overlooked specialty drug market?
Regional Marketing, National Growth
By Jeffrey Spanbauer
Pharm Exec sits down with an expert on regional marketing to ascertain what it takes to drive strong brand results
Lifting the Veil
By Jon Zifferblatt
A shakeout is ahead as China restructures its murky and insular system of drug distribution
Integrating R&D Within M&As
By Rick Heinick
The CEO should be able to communicate the vision of a merger—strategically, financially, operationally, and with the entire organization in mind
Comparisons and Costs
By Jill Wechsler
PCORI is independent and transparent and likely to alter methods for assesssing the value of new therapies
Sponsored Content
Country Report: The Philippines
By Focus Reports
Once silent, an emerging market raises its voice
Back Page
How the FDA Grew
By Walter Armstrong
A timeline of some of the landmark legislation, court decisions, and drug scandals that helped forge the FDA
From the Editor
Pharma's Identity, From I to T
By William Looney
The FDA process itself is looking more like the unsavory 'sausage factory' associated with drafting partisan legislation

ADVERTISEMENT

Click here